Welcome to our dedicated page for BiondVax Pharmaceuticals Ltd. news (Ticker: bvxv), a resource for investors and traders seeking the latest updates and insights on BiondVax Pharmaceuticals Ltd. stock.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a biopharmaceutical company pioneering innovative solutions in the realm of inflammation and immunology (I&I). With a robust pipeline of nanosized VHH antibodies known as NanoAbs, BiondVax is targeting diseases with significant unmet medical needs. The company has made notable strides, particularly with its leading product, an intradermal NanoAb targeting IL-17 for treating mild to moderate plaque psoriasis. This product has shown promising results in preclinical ex-vivo trials and is gearing up for human clinical trials in 2025.
BiondVax operates two main business units. The first focuses on the in-house development of biological therapeutic products, leveraging its NanoAb technology licensed from the Max Planck Society and the University Medical Center Göttingen, Germany. The second unit, Scinai Bioservices, is a boutique Contract Development and Manufacturing Organization (CDMO) that offers end-to-end services ranging from drug development to GMP manufacturing. Launched in Q3 2023, Scinai Bioservices has already secured contracts with several biotechnology companies and aims to support small biotech firms in bringing their products to market efficiently.
The company recently welcomed Liat Halpert as Head of Business Development and Sales. Halpert, with her extensive experience from Novartis, is expected to expand Scinai’s CDMO business, particularly targeting European and U.S.-based biotech companies. This strategic move is anticipated to significantly boost BiondVax's revenue and establish it as a key partner for small biotechnology firms.
In recent news, BiondVax announced successful preclinical results of its IL-17 targeting NanoAb for psoriasis treatment. Additionally, its NanoAbs for COVID-19 have shown efficacy in preclinical trials, demonstrating potential in preventing and treating viral respiratory diseases through inhalation, a convenient administration route.
BiondVax's financial stability and strategic partnerships position it well for future growth. The company continues to seek collaborative opportunities with mid and large-cap pharmaceutical companies to advance its NanoAb therapies through clinical trials and towards commercialization.
For the latest updates and detailed information, visit BiondVax’s official website at www.biondvax.com.
The U.S. influenza vaccines market was valued at US$ 3,962 million in 2022 and is projected to reach US$ 8,347 million by 2031, witnessing a CAGR of 8.6%. This growth is driven by increasing R&D, the launch of quadrivalent vaccines, an aging population, and heightened vaccine awareness. The U.S. remains the largest influenza vaccines market globally. Key market participants include BiondVax Pharmaceuticals (BVXV), Novavax, and GSK, among others. The report provides insights into market dynamics, vaccination trends, pricing analysis, and regulatory frameworks from 2018 to 2031. Additionally, the ongoing COVID-19 pandemic is expected to further drive demand for influenza vaccines.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) reported its full-year financial results for 2022, revealing a net loss of $5.8 million compared to $8.2 million in 2021. Key developments included an increase in R&D expenses to $5.7 million from $3.2 million and a reduction in marketing, general, and administrative expenses to $5.3 million from $7.6 million. The company reported total operating expenses of $11.06 million, up from $10.8 million in 2021, while financial income rose to $5.2 million from $2.6 million, largely due to currency exchange benefits. As of December 31, 2022, BiondVax had cash reserves of $14 million, down from $17.3 million in 2021. The company is advancing its pipeline of nanosized VHH antibodies (NanoAbs) and plans to focus on clinical trials for COVID-19 therapies while managing the risks posed by evolving virus variants.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced that CEO Amir Reichman will present at the 17th annual BIO-Europe Spring from March 20-22, 2023, in Basel, Switzerland. This major biotech conference expects over 2,800 executives and 15,000+ one-on-one meetings. Reichman's presentation on March 21 at 11:30 a.m. will highlight successful preclinical in vivo results of BiondVax's innovative inhaled COVID-19 treatment and upcoming plans for nanosized VHH-antibodies aimed at treating autoimmune diseases like psoriasis and asthma. BiondVax's robust R&D strategy emphasizes developing a pipeline of effective treatments addressing significant medical needs.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced that CEO Amir Reichman will present at the BIO CEO & Investor Conference from Feb. 6-9, 2023, in New York. The presentation will highlight recent successful preclinical in vivo results for BiondVax's inhaled COVID-19 treatment and the development of nanosized VHH-antibodies (NanoAbs) targeting autoimmune diseases like psoriasis and asthma. The company aims to create a pipeline of innovative products addressing underserved medical needs. Attendees are encouraged to schedule meetings with BiondVax leaders at the conference.
BiondVax Pharmaceuticals (Nasdaq: BVXV) announced promising results from a preclinical study on its inhaled anti-COVID-19 treatment, utilizing nanosized antibodies (NanoAbs). In hamsters, those treated with NanoAbs exhibited over 30 times lower lung viral titers compared to a placebo group, suggesting significant efficacy. The study also showed that treated animals experienced milder illness and faster recovery. A Phase 1/2a clinical trial is set to begin in late 2023, aiming to develop this therapy for COVID-19 and other diseases with high unmet medical needs, such as psoriasis and asthma.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced that CEO Amir Reichman will present at the Biotech Showcase conference from January 9-11, 2023, in San Francisco. The presentation, scheduled for January 9 at 9:30 a.m. PT, will cover successful preclinical trial results of BiondVax's inhaled COVID-19 therapy and plans for a nanosized antibody (NanoAb) pipeline targeting autoimmune diseases. This opportunity aims to highlight BiondVax’s innovative approach in addressing unmet medical needs. For one-on-one meetings, interested parties can use the Biotech Showcase partnering platform.
BiondVax Pharmaceuticals (Nasdaq: BVXV) released a letter from CEO Amir Reichman detailing 2022 milestones and future objectives. Key achievements include successful preclinical results for an inhaled COVID-19 NanoAb therapy and significant financing efforts. The company entered collaborations with Max Planck Institute and University Medical Center Göttingen to develop innovative nanosized antibodies, targeting unmet medical needs. BiondVax aims to initiate Phase 1/2a clinical trials for the COVID-19 therapy in late 2023, supported by a robust funding strategy.
BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) has completed an $8 million underwritten public offering, with Aegis Capital Corp. serving as the sole bookrunner. The company, headquartered in Jerusalem, focuses on developing treatments for infectious diseases and has collaborations for COVID-19 nanosized antibody (NanoAb) development. BiondVax aims to commercialize NanoAbs for various diseases. This funding is expected to support its research and development efforts.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) has successfully closed an underwritten public offering, raising $8 million in gross proceeds. The offering includes 1,600,000 units, where each unit consists of one American Depositary Share (ADS) and two warrants. Each ADS represents 400 ordinary shares. The company plans to deploy the net proceeds towards the advancement of its NanoAbs development program and general corporate purposes. Aegis Capital Corp. served as the sole book-running manager for this offering.
FAQ
What is the market cap of BiondVax Pharmaceuticals Ltd. (bvxv)?
What does BiondVax Pharmaceuticals Ltd. do?
What are NanoAbs?
What recent achievements has BiondVax made?
Who is Liat Halpert?
What services does Scinai Bioservices offer?
When are human clinical trials for the psoriasis NanoAb expected?
What are the potential applications of BiondVax's NanoAbs?
How is BiondVax planning to expand its CDMO business?
What regulatory approvals does BiondVax need?
Where can I find more information about BiondVax Pharmaceuticals Ltd.?
